Sleep Cycle AB (publ)

OM:SLEEP Stock Report

Market Cap: SEK 320.4m

Sleep Cycle Management

Management criteria checks 2/4

Sleep Cycle's CEO is Erik Jivmark, appointed in Nov 2023, has a tenure of 2.5 years. total yearly compensation is SEK4.67M, comprised of 60.4% salary and 39.6% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth SEK869.01K. The average tenure of the management team and the board of directors is 2.1 years and 2.9 years respectively.

Key information

Erik Jivmark

Chief executive officer

SEK 4.7m

Total compensation

CEO salary percentage60.40%
CEO tenure2.5yrs
CEO ownership0.3%
Management average tenure2.1yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Narrative Update May 07

SLEEP: Respiratory Research And Sleep Apnea Solution Will Drive Long Term Upside

Analysts have trimmed their price target on Sleep Cycle from SEK30.75 to about SEK28.83, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping the app included in exclusive offerings for Premium, Metal and Ultra customers and giving access to a large, premium user base for its sleep optimization features (Client Announcements).
Analysis Article May 02

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...
Narrative Update Apr 21

SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery

Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
Narrative Update Apr 04

SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential

Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.
Narrative Update Mar 21

SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside

Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.
Narrative Update Mar 06

SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside

Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.
Narrative Update Feb 19

SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside

Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.
Analysis Article Feb 09

These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

One thing we could say about the analysts on Sleep Cycle AB (publ) ( STO:SLEEP ) - they aren't optimistic, having just...
Analysis Article Feb 07

Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

Sleep Cycle AB (publ) ( STO:SLEEP ) is reducing its dividend from last year's comparable payment to SEK0.53 on the 20th...
Narrative Update Feb 04

SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play

Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).
Narrative Update Jan 21

SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside

Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.
Narrative Update Jan 06

SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside

Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).
Analysis Article Jan 04

There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

Sleep Cycle AB (publ)'s ( STO:SLEEP ) price-to-earnings (or "P/E") ratio of 9.2x might make it look like a strong buy...
Narrative Update Dec 15

SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential

Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.
Analysis Article Sep 09

Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a really impressive month, gaining 30% after a shaky period...
Analysis Article Aug 27

Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

The main catalyst behind Sleep Cycle’s upside potential, why JB Hi-Fi might have lost its point of difference, and the bear, base and bull case for Figma.
Narrative Update Aug 23

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.
Narrative Update Aug 22

Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities

Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.
Analysis Article Apr 30

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...
Analysis Article Apr 29

The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a horrible month, losing 34% after a relatively good period...
Analysis Article Apr 08

Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00

Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
User avatar
New Narrative Mar 18

Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships

Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.
Analysis Article Mar 06

Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
Analysis Article Feb 10

Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Sleep Cycle AB (publ) ( STO:SLEEP ) will increase its dividend from last year's comparable payment on the 15th of April...
New Narrative Feb 10

Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model

Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device for

CEO Compensation Analysis

How has Erik Jivmark's remuneration changed compared to Sleep Cycle's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

SEK 45m

Dec 31 2025SEK 5mSEK 3m

SEK 53m

Sep 30 2025n/an/a

SEK 59m

Jun 30 2025n/an/a

SEK 62m

Mar 31 2025n/an/a

SEK 65m

Dec 31 2024SEK 6mSEK 3m

SEK 63m

Sep 30 2024n/an/a

SEK 56m

Jun 30 2024n/an/a

SEK 55m

Mar 31 2024n/an/a

SEK 49m

Dec 31 2023SEK 3mSEK 440k

SEK 46m

Compensation vs Market: Erik's total compensation ($USD507.12K) is above average for companies of similar size in the Swedish market ($USD322.67K).

Compensation vs Earnings: Erik's compensation has been consistent with company performance over the past year.


CEO

Erik Jivmark (43 yo)

2.5yrs
Tenure
SEK 4,669,000
Compensation

Mr. Erik Jivmark is Chief Executive Officer of Sleep Cycle AB (publ) from November 1, 2023. He is an experienced CEO with growth mindset and has extensive international experience from leading positions wi...


Leadership Team

NamePositionTenureCompensationOwnership
Erik Jivmark
Chief Executive Officer2.5yrsSEK 4.67m0.27%
SEK 869.0k
Elisabeth Hedman
CFO & Head of Investor Relations1.9yrsno data0.0099%
SEK 31.6k
Mikael Kageback
Chief Technology Officer6.3yrsno data0.099%
SEK 316.0k
Mike Gradisar
Head of Sleep Science4yrsno datano data
Peter Alsterberg
Chief Commercial Officer2.1yrsno data0.049%
SEK 158.0k
Petter Hoglander
Chief Product Officer2.1yrsno data0.024%
SEK 75.8k
Joanna Widestrand
Head of Quality & Compliance for Medical Deviceless than a yearno datano data
Malin Johansson
Head of Life Science Partnershipsless than a yearno datano data
2.1yrs
Average Tenure
43yo
Average Age

Experienced Management: SLEEP's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anne Broeng
Independent Chairperson26.3yrsSEK 912.00k0.049%
SEK 158.0k
Christian Kanstrup
Directorless than a yearSEK 53.00kno data
Maciej Drejak
Director2.8yrsSEK 294.00k42.94%
SEK 137.6m
Mathias Hoyer
Independent Director3yrsSEK 426.00k0.070%
SEK 222.9k
2.9yrs
Average Tenure
50yo
Average Age

Experienced Board: SLEEP's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/08 16:46
End of Day Share Price 2026/05/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sleep Cycle AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar ErixonCarnegie Investment Bank AB
Erik GranströmDNB Carnegie
Rikard EngbergDNB Carnegie Commissioned Research